Status:
ENROLLING_BY_INVITATION
KardiaMobile ECG Monitoring Effects on Health Care Utilization and Patient Experience With Atrial Fibrillation
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
Cardiovascular Institute of the South Clinical Research Corporation
Conditions:
Atrial Fibrillation (AF)
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
This is a two-center, randomized controlled trial of 100 patients comparing intervention (KardiaMobile) with standard of care. Kardia Mobile is an FDA approved device that allows one- or six lead ECG ...
Eligibility Criteria
Inclusion
- 18-90 years of age,
- Diagnosis of atrial fibrillation within the last 6 months,
- Possession of a smart phone with active cell service,
- Physical and cognitive ability to self-record reliable ECG tracings on the KardiaMobile device,
- Life expectancy \>12 months.
Exclusion
- Resting tremor
- Has an intracardiac lead.
- Has an implanted loop recorder.
- Already has an apple watch, FitBit, or other mobile ECG recorder.
- Those who are non-English speaking, pregnant, or a prisoner.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05407415
Start Date
September 1 2022
End Date
December 1 2025
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611